|Mr. Michael E. Macaluso||Founder, Chairman & CEO||457.04k||N/A||1952|
|Mr. Daniel G. Stokely CPA, CPA||CFO, Corp. Sec. & Treasurer||419.5k||N/A||1964|
|Ms. Holli Cherevka||Chief Operating Officer||288.04k||N/A||1983|
|Lane Hapke||VP of Manufacturing Operations||N/A||N/A||N/A|
|April Ramirez||Clinical Trial Mang.||N/A||N/A||N/A|
|Laura Goldberg||VP of Quality and Regulatory Operations||N/A||N/A||N/A|
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is headquartered in Englewood, Colorado.
Ampio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.